Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.39 |
| ▸ | FLT1 | P17948 | 12/20 | 0.39 |
| ▸ | FLT4 | P35916 | 12/20 | 0.39 |
| ▸ | CLK1 | P49759 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2874945 | 0.92 | KDR (0.40) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL31672520 | 0.92 | KDR (0.40) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL10151177 | 0.88 | KDR (0.47) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL31672398 | 0.88 | KDR (0.47) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL10151185 | 0.86 | KDR (0.38) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL31672481 | 0.86 | KDR (0.38) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL7139449 | 0.85 | KDR (0.36) | KDRFLT1FLT4CLK1DYRK1A | |
| SCHEMBL10151221 | 0.80 | KDR (0.47) | KDRFLT1FLT4PARP1 | |
| SCHEMBL31672413 | 0.80 | KDR (0.47) | KDRFLT1FLT4PARP1 | |
| SCHEMBL30453672 | 0.80 | KDR (0.53) | KDRFLT1FLT4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | claimed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | claimed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | claimed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | claimed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-113181362-A | Agent for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | KDR 5/4885FLT1 6/4885FLT4 4/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885FLT4 2/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | KDR 648/4885FLT1 659/4885FLT4 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.